RARE Ultragenyx Pharmaceutical (RARE) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001515673
Congress · 1Form 144 · 2
Insider buyers, 180 days
0
Funds added, last quarter
175
13F, latest reported quarter
What the filings say about RARE
Insiders, 180 days
-$924.4K net sold
6 sellers · 8% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-29
Planned sales (Form 144), 90 days
$134.5K
2 notices
Ultragenyx Pharmaceutical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Ultragenyx Pharmaceutical Inc. insiders sold a net $924.4K of stock across 120 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on Aug 3, 2026.
- The trade is 7.9% of the 89,229 shares held after it.
- 1 other insider sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Horn Howard sold about $107.9K of RARE on Oct 15, 2026; 1 other insider sold within 30 days and 175 funds added in the latest 13F quarter.Context
- 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Sep 3, 2026.
- The trade is 1.9% of the 67,863 shares held after it.
- 1 other insider sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Accounting Officer Huizenga Theodore Alan sold about $17.4K of RARE under a 10b5-1 plan on Sep 15, 2026; 1 other insider sold within 30 days and 175 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Mar 2, 2026.
- The trade is 0.2% of the 69,146 shares held after it.
- No other insider sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Accounting Officer Huizenga Theodore Alan sold about $2.3K of RARE on Sep 3, 2026; 175 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jul 1, 2026.
- The trade is 4.9% of the 96,295 shares held after it.
- 1 other insider sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Horn Howard sold about $117.0K of RARE on Aug 3, 2026; 1 other insider sold within 30 days and 175 funds added in the latest 13F quarter.Context
- 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Jun 15, 2026.
- The trade is 2.1% of the 92,562 shares held after it.
- 1 other insider sold within 30 days.
- 175 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP and Chief Legal Officer Parschauer Karah Herdman sold about $47.3K of RARE on Aug 3, 2026; 1 other insider sold within 30 days and 175 funds added in the latest 13F quarter.120 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$924.4K over 180 days
-$291.9K over 90 days
below 61% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
175 funds bought in last quarter
more than 86% of Pharma & Biotech
Revenue
+20.2% year over year
more than 66% of Pharma & Biotech
Margin
-85.4% net margin
below 56% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
27.5% of the float short (float per yahoo 2026-10-26) · 3.1 days to cover · settled 2026-09-30
more than 95% of Pharma & Biotech
What changed in the last 30 days
Oct 19Chief Financial Officer Horn Howard sold $107.9K (Oct 15)
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch RARE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-52.8%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RARE: institutional holders (13F)
13F holdings, latest reported quarter
10,654,276 sh
$355.7M
7,796,895 sh
$260.3M
6,790,135 sh
$226.7M
6,560,809 sh
$214.1M
6,158,766 sh
$205.6M
Congress trades in RARE
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-29 · disclosed 13 days later
$1,001 - $15,000
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Bought 2026-02-18 · disclosed 19 days later
$1,001 - $15,000
Bought 2025-08-08 · disclosed 35 days later
$1,001 - $15,000
Bought 2025-07-15 · disclosed 30 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RARE planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
THEODORE HUIZENGA
Filed 2026-09-15
$17.5K
HOWARD HORN
Filed 2026-08-03
$117.0K
HOWARD HORN
Filed 2026-07-01
$155.6K
RARE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Motley Fool Small-Cap Growth ETF
$1.8M position · as of 2026-05-31
3.0%
Global X Genomics & Biotechnology ETF
$1.3M position · as of 2026-05-31
2.2%
ALGER WEATHERBIE SPECIALIZED GROWTH FUND
$4.9M position · as of 2026-07-31
2.0%
Virtus Biotech Etf
$1.4M position · as of 2026-07-31
1.4%
AMG Frontier Small Cap Growth Fund
$1.3M position · as of 2026-07-31
1.4%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$122.4M position · as of 2026-06-30
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
35 registered trials, 19 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 2
1 active
9
Phase 3
7 active
13
Not applicable
7 active
8
Multi-phase
4 active
What changed recently
Long-term Extension of GTX-102 in Angelman Syndrome
2026-09-10 · Enrolling By Invitation → Active Not Recruiting
Phase 3
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type An
2026-09-10 · Recruiting → Active Not Recruiting
Phase 2
First-in-human Study of UX016 in GNEM
2026-09-04 · Not Yet Recruiting → Recruiting
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Ultragenyx Pharmaceutical Inc. Political Action Committee (Aka Ultragenyx Pac)
Cycle 2026 · $62K spent
$49.0K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Dr. Kakkis
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$11.4M
-$1.3M
$3.8M
-83%
+20%
2024
$13.7M
$8.2M
$4.3M
-70%
-9%
2023
$13.1M
$11.3M
$4.5M
-65%
-8%
2022
$12.1M
$3.3M
$3.9M
-67%
-11%
2021
$9.5M
-$2.2M
$3.3M
-39%
-1%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $924.4K sold by insiders over 180 days, 175 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $134.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
RARE financials
Revenue growth
+20.2%
XBRL, annual
Net margin
-85.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$717.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RARE
| FY Dec 2025 | $673.5M |
| FY Dec 2024 | $560.2M |
| FY Dec 2023 | $434.2M |
| FY Dec 2022 | $363.3M |
| FY Dec 2021 | $351.4M |
| Jun 2026 | $214.0M |
| Mar 2026 | $136.0M |
| Dec 2025 | $207.3M |
| Sep 2025 | $159.9M |
| Jun 2025 | $167.0M |
| Mar 2025 | $139.3M |
| Dec 2024 | $164.9M |
| Sep 2024 | $139.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-81.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RARE
| FY Dec 2025 | -85.4% |
| FY Dec 2024 | -101.6% |
| FY Dec 2023 | -139.8% |
| FY Dec 2022 | -194.7% |
| FY Dec 2021 | -129.2% |
| Jun 2026 | -43.0% |
| Mar 2026 | -136.0% |
| Dec 2025 | -62.0% |
| Sep 2025 | -112.8% |
| Jun 2025 | -68.9% |
| Mar 2025 | -108.4% |
| Dec 2024 | -80.8% |
| Sep 2024 | -95.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$489.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RARE
| FY Dec 2025 | -$472.0M |
| FY Dec 2024 | -$421.0M |
| FY Dec 2023 | -$519.0M |
| FY Dec 2022 | -$496.6M |
| FY Dec 2021 | -$411.8M |
| Jun 2026 | -$98.0M |
| Mar 2026 | -$198.0M |
| Dec 2025 | -$100.8M |
| Sep 2025 | -$92.2M |
| Jun 2025 | -$112.0M |
| Mar 2025 | -$167.0M |
| Dec 2024 | -$79.5M |
| Sep 2024 | -$68.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity RARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt RARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity RARE
| FY Dec 2025 | -657.1% |
| FY Dec 2024 | -214.7% |
| FY Dec 2023 | -193.6% |
| FY Dec 2022 | -111.0% |
| FY Dec 2021 | -43.7% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -657.1% |
| Sep 2025 | -325.6% |
| Jun 2025 | -182.6% |
| Mar 2025 | -386.5% |
| Dec 2024 | -214.7% |
| Sep 2024 | -295.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-45.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RARE
| FY Dec 2025 | -37.9% |
| FY Dec 2024 | -38.0% |
| FY Dec 2023 | -40.0% |
| FY Dec 2022 | -46.1% |
| FY Dec 2021 | -27.7% |
| Jun 2026 | -45.6% |
| Mar 2026 | -46.7% |
| Dec 2025 | -37.9% |
| Sep 2025 | -42.5% |
| Jun 2025 | -36.4% |
| Mar 2025 | -41.9% |
| Dec 2024 | -38.0% |
| Sep 2024 | -40.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital RARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-54.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RARE
| FY Dec 2025 | -46.4% |
| FY Dec 2024 | -45.2% |
| FY Dec 2023 | -45.6% |
| FY Dec 2022 | -49.4% |
| FY Dec 2021 | -26.2% |
| Jun 2026 | -54.8% |
| Mar 2026 | -56.4% |
| Dec 2025 | -46.4% |
| Sep 2025 | -51.7% |
| Jun 2025 | -42.8% |
| Mar 2025 | -49.3% |
| Dec 2024 | -45.2% |
| Sep 2024 | -47.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value RARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-31.7%
TTM free cash flow over market value at close 2026-10-23
FCF yield RARE
| FY Dec 2025 | -21.3% |
| FY Dec 2024 | -10.8% |
| FY Dec 2023 | -13.2% |
| FY Dec 2022 | -15.3% |
| FY Dec 2021 | -7.2% |
| Jun 2026 | -14.9% |
| Mar 2026 | -24.8% |
| Dec 2025 | -21.3% |
| Sep 2025 | -15.5% |
| Jun 2025 | -12.4% |
| Mar 2025 | -11.8% |
| Dec 2024 | -10.8% |
| Sep 2024 | -8.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RARE
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $673.0M | $560.2M | $434.2M | $363.3M |
| Operating income | -$535.0M | -$536.0M | -$569.0M | -$648.9M |
| Net income | -$575.0M | -$569.0M | -$607.0M | -$707.4M |
| EPS (diluted) | -5.83 | -6.29 | -8.25 | -10.12 |
| Operating cash flow | -$466.0M | -$414.0M | -$475.0M | -$380.5M |
| Cash | $421.0M | $174.0M | $214.0M | $132.9M |
SEC XBRL, fiscal years, as known on 2026-10-27
RARE Stock Sonar score 5/7 axes
Find similar shapesCompareRARE ranks highest on institutional and government (76th percentile) and growth (66th), and lowest on insider conviction (19th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RARE filings, in plain words
Are Ultragenyx Pharmaceutical insiders buying or selling RARE?
In the 180 days to 2026-10-27, Ultragenyx Pharmaceutical insiders were net sellers, a net $924.4K across purchases and sales reported on Form 4, by 6 sellers.
Have members of Congress traded RARE?
Yes. In the year to 2026-10-27, 1 House member disclosed buying RARE and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29.
Are there planned insider sales of RARE?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $134.5K of stock; the latest, by THEODORE HUIZENGA, was filed 2026-09-15.
Read the full summary
In the 180 days to 2026-10-27, Ultragenyx Pharmaceutical insiders were net sellers of RARE, a net $924.4K across purchases and sales reported on Form 4 by 6 sellers. 8% of the 12 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-27, 1 member of Congress disclosed buying RARE and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-09-29. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $134.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
